Efficacy of Cevimeline on Xerostomia in Sjögren's Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Surprisingly, contrary to previous findings, this study did not observe enhancements in salivary secretion or oral health status, despite a positive trend noted in the latter measures. 15 Additionally, Papas et al 34 demonstrated significant improvement in ocular symptoms with a dosage escalation to 30 mg/day, alongside notable relief in dry mouth symptoms at a dosage of 20 mg/day. 34 Yamada et al 35 revealed through parotid sialography that Sjögren's syndrome patients with sialectasis exhibited reduced sensitivity to cevimeline compared to those without this condition.

also in 11,005 other papers